KR20170002425A - 공막의 의학적 치료용 장치 - Google Patents
공막의 의학적 치료용 장치 Download PDFInfo
- Publication number
- KR20170002425A KR20170002425A KR1020167031218A KR20167031218A KR20170002425A KR 20170002425 A KR20170002425 A KR 20170002425A KR 1020167031218 A KR1020167031218 A KR 1020167031218A KR 20167031218 A KR20167031218 A KR 20167031218A KR 20170002425 A KR20170002425 A KR 20170002425A
- Authority
- KR
- South Korea
- Prior art keywords
- application device
- optical
- sclera
- application
- shaft
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003786 sclera Anatomy 0.000 title claims abstract description 151
- 238000011282 treatment Methods 0.000 title claims abstract description 80
- 230000003287 optical effect Effects 0.000 claims abstract description 225
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 38
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 36
- 230000015271 coagulation Effects 0.000 claims abstract description 33
- 238000005345 coagulation Methods 0.000 claims abstract description 33
- 238000007669 thermal treatment Methods 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims description 258
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 121
- 238000000034 method Methods 0.000 claims description 82
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 61
- 229960002477 riboflavin Drugs 0.000 claims description 61
- 235000019192 riboflavin Nutrition 0.000 claims description 60
- 239000002151 riboflavin Substances 0.000 claims description 60
- 230000005670 electromagnetic radiation Effects 0.000 claims description 45
- 238000004132 cross linking Methods 0.000 claims description 41
- 238000009826 distribution Methods 0.000 claims description 31
- 239000004020 conductor Substances 0.000 claims description 27
- 210000003205 muscle Anatomy 0.000 claims description 21
- 210000004087 cornea Anatomy 0.000 claims description 13
- 239000003504 photosensitizing agent Substances 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 8
- 239000004033 plastic Substances 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 229910000831 Steel Inorganic materials 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 239000003779 heat-resistant material Substances 0.000 claims description 3
- 239000007769 metal material Substances 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 239000010959 steel Substances 0.000 claims description 3
- 210000001508 eye Anatomy 0.000 description 79
- 210000001519 tissue Anatomy 0.000 description 73
- 239000000126 substance Substances 0.000 description 42
- 230000005855 radiation Effects 0.000 description 38
- 102000008186 Collagen Human genes 0.000 description 30
- 108010035532 Collagen Proteins 0.000 description 30
- 229920001436 collagen Polymers 0.000 description 30
- 238000001356 surgical procedure Methods 0.000 description 24
- 239000003814 drug Substances 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000013459 approach Methods 0.000 description 11
- 210000000795 conjunctiva Anatomy 0.000 description 11
- 239000013307 optical fiber Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 210000003484 anatomy Anatomy 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000001309 degenerative myopia Diseases 0.000 description 8
- 230000036285 pathological change Effects 0.000 description 8
- 230000004515 progressive myopia Effects 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000000744 eyelid Anatomy 0.000 description 7
- 231100000915 pathological change Toxicity 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000004040 coloring Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010039705 Scleritis Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000002962 histologic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002690 local anesthesia Methods 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 229950003937 tolonium Drugs 0.000 description 3
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000005404 monopole Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229960004175 xylazine hydrochloride Drugs 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 241000032989 Ipomoea lacunosa Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 206010057765 Procedural complication Diseases 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 239000004228 Riboflavin-5'-Phosphate Substances 0.000 description 1
- 241000711981 Sais Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 239000000382 optic material Substances 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000004286 retinal pathology Effects 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000007751 thermal spraying Methods 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/00821—Methods or devices for eye surgery using laser for coagulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00853—Laser thermal keratoplasty or radial keratotomy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00865—Sclera
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Radiation-Therapy Devices (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14164091.2 | 2014-04-09 | ||
| EP14164091 | 2014-04-09 | ||
| PCT/EP2015/057319 WO2015155117A1 (en) | 2014-04-09 | 2015-04-02 | A device for a medical treatment of a sclera |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170002425A true KR20170002425A (ko) | 2017-01-06 |
Family
ID=50478256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167031218A Withdrawn KR20170002425A (ko) | 2014-04-09 | 2015-04-02 | 공막의 의학적 치료용 장치 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10426663B2 (enExample) |
| EP (1) | EP3128966A1 (enExample) |
| JP (1) | JP6554118B2 (enExample) |
| KR (1) | KR20170002425A (enExample) |
| CN (1) | CN106413644B (enExample) |
| BR (1) | BR112016023453A2 (enExample) |
| SG (1) | SG11201608257RA (enExample) |
| WO (1) | WO2015155117A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| WO2013149075A1 (en) | 2012-03-29 | 2013-10-03 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| ES2978927T3 (es) | 2012-03-29 | 2024-09-23 | Epion Therapeutics Inc | Soluciones de tratamiento ocular, dispositivos de administración y métodos de aumento de la administración |
| US10960224B2 (en) | 2017-01-12 | 2021-03-30 | Janssen Pharmaceutica Nv | Trans-orbital infrared light therapy |
| US20220401261A1 (en) * | 2017-12-07 | 2022-12-22 | Harry Michael Lambert | Ophthalmological surgery microsurgery instruments and methods of use in pars plana vitrectomy for increasing surgical precision and reducing vitreoretinal instrument insertions and removals and related trauma |
| KR20250109788A (ko) * | 2018-01-05 | 2025-07-17 | 유니버시티 오브 유타 리서치 파운데이션 | 근시 진행의 치료 |
| US11890233B2 (en) * | 2019-04-04 | 2024-02-06 | California Institute Of Technology | Systems and methods for drug delivery |
| US10874874B2 (en) * | 2019-04-15 | 2020-12-29 | Janssen Pharmaceutica Nv | Transorbital NIR light therapy device |
| US10926102B2 (en) | 2019-04-15 | 2021-02-23 | Janssen Pharmaceutica Nv | Transorbital NIR LIGHT THERAPY DEVICES |
| TW202216153A (zh) * | 2020-07-21 | 2022-05-01 | 日商參天製藥股份有限公司 | 基於膠原纖維之交聯的眼部疾病之預防及/或治療 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5423800A (en) * | 1992-10-19 | 1995-06-13 | The University Of Miami | Laser scleral buckling method and instruments therefor |
| US5342355A (en) * | 1992-10-19 | 1994-08-30 | Laser Centers Of America | Energy delivering cap element for end of optic fiber conveying laser energy |
| US5688264A (en) | 1992-10-19 | 1997-11-18 | The University Of Miami | Laser treatment for retinal detachment |
| US6413245B1 (en) * | 1999-10-21 | 2002-07-02 | Alcon Universal Ltd. | Sub-tenon drug delivery |
| US7044945B2 (en) | 2001-03-30 | 2006-05-16 | Sand Bruce J | Prevention of regression in thermal ciliary muscle tendinoplasty |
| US8403828B2 (en) | 2003-07-21 | 2013-03-26 | Vanderbilt University | Ophthalmic orbital surgery apparatus and method and image-guide navigation system |
| DE602005026978D1 (de) * | 2004-11-23 | 2011-04-28 | Timothy L Lee | Medizinische vorrichtung zur temperaturregelung und behandlung des auges sowie des umgebenden gewebes |
| WO2008124009A2 (en) * | 2007-04-02 | 2008-10-16 | The Cleveland Clinic Foundation | Treating glaucoma |
| JP5487470B2 (ja) | 2010-03-31 | 2014-05-07 | ソニー株式会社 | 後部強膜硬化装置 |
| WO2012112543A2 (en) | 2011-02-15 | 2012-08-23 | Seros Medical, Llc | Method and apparatus for the delivery of photo-chemical (cross-linking) treatment to scleral tissue |
| WO2012154627A2 (en) * | 2011-05-06 | 2012-11-15 | California Institute Of Technology | Light delivery device and related compositions, methods and systems |
| EP3441049B1 (en) | 2013-03-14 | 2025-08-20 | Epion Therapeutics, Inc. | Ophthalmic treatment device |
-
2015
- 2015-04-02 BR BR112016023453A patent/BR112016023453A2/pt not_active IP Right Cessation
- 2015-04-02 JP JP2016561715A patent/JP6554118B2/ja not_active Expired - Fee Related
- 2015-04-02 KR KR1020167031218A patent/KR20170002425A/ko not_active Withdrawn
- 2015-04-02 SG SG11201608257RA patent/SG11201608257RA/en unknown
- 2015-04-02 CN CN201580026760.2A patent/CN106413644B/zh not_active Expired - Fee Related
- 2015-04-02 US US15/302,854 patent/US10426663B2/en not_active Expired - Fee Related
- 2015-04-02 EP EP15716003.7A patent/EP3128966A1/en not_active Withdrawn
- 2015-04-02 WO PCT/EP2015/057319 patent/WO2015155117A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN106413644B (zh) | 2020-01-17 |
| BR112016023453A2 (pt) | 2021-06-01 |
| JP6554118B2 (ja) | 2019-07-31 |
| WO2015155117A1 (en) | 2015-10-15 |
| EP3128966A1 (en) | 2017-02-15 |
| SG11201608257RA (en) | 2016-10-28 |
| US20170087017A1 (en) | 2017-03-30 |
| CN106413644A (zh) | 2017-02-15 |
| US10426663B2 (en) | 2019-10-01 |
| JP2017514564A (ja) | 2017-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9889041B2 (en) | Device for a medical treatment of a sclera | |
| US10426663B2 (en) | Device for a medical treatment of a sclera | |
| Souissi et al. | An update on continuous‐wave cyclophotocoagulation (CW‐CPC) and micropulse transscleral laser treatment (MP‐TLT) for adult and paediatric refractory glaucoma | |
| Asbell et al. | Conductive keratoplasty for the correction of hyperopia | |
| McDonald et al. | Conductive keratoplasty for the correction of low to moderate hyperopia: US clinical trial 1-year results on 355 eyes | |
| US20220280343A1 (en) | Excimer laser fiber illumination | |
| US9962291B2 (en) | System and process for neuroprotective therapy for glaucoma | |
| US8602959B1 (en) | Methods and devices for delivery of radiation to the posterior portion of the eye | |
| US8141557B2 (en) | Method of oscillatory thermotherapy of biological tissue | |
| JP2017506562A (ja) | レーザエネルギ送達のための照明付き治療プローブ | |
| JPH09504447A (ja) | 熱手段による視力の変更 | |
| Giannaccare et al. | Ultrasound cyclo plasty in eyes with glaucoma | |
| CN101296676B (zh) | 黄斑变性的治疗设备 | |
| Matsuo et al. | Subretinal implantation of Okayama University-type retinal prosthesis (OURePTM) in canine eyes by vitrectomy | |
| ES2952701T3 (es) | Sistema y procedimiento para terapia neuroprotectora del glaucoma | |
| RU2472476C1 (ru) | Способ лазерного лечения сливных друз при возрастной макулярной дегенерации | |
| HK1229679A1 (en) | A device for a medical treatment of a sclera | |
| RU2201187C1 (ru) | Способ лечения новообразованных сосудов сетчатки | |
| RU2780277C1 (ru) | Способ проведения микроимпульсной транссклеральной циклофотокоагуляции при рефрактерной глаукоме | |
| RU2308255C1 (ru) | Способ лечения рефракторной глаукомы | |
| RU2251396C2 (ru) | Способ лечения осложнения после лазерного кератомилеза | |
| RU2297819C1 (ru) | Способ лечения внутриглазной опухоли | |
| RU2452445C1 (ru) | Способ микроимпульсного лазерного лечения центральной серозной хориоретинопатии у больных с противопоказаниями к проведению флюоресцентной ангиографии | |
| KERATOPLASTY | Conductive Keratoplasty for the Correction of Low to Moderate Hyperopia | |
| UA11831U (en) | Method for combined treatment of subretinal neovascular membranes of subfoveal location |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20161108 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200214 Comment text: Request for Examination of Application |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20200824 |
|
| WITB | Written withdrawal of application |